November 18, 2009
– Comments (4) |
RELATED TICKERS: VVUS
Which is actually good for us that know a good thing when we see it.
Are you serious? I shorted this company many times in the past. It is such a fraud. Are they still on the obesity drug or did they come up with something else already to lead investors on?
I am not short it right now.
What would be the point? Caps shows that TrackJimCrammer placed an underperform call on 10/2/2009?
I think they are shorting Jim Cramer's pick more than the company.
CNBC's biotech guru Mike Huckman pointing out that big pharmas are cash rich and patent poor. Time is short and the big pharmas can't afford to keep spending money on failed clinical trials as they search for the next blockbuster drug. That brings us back to Vivus, whose product pipeline includes three late-stage clinical products, each addressing specific components of the obesity, diabetes and sexual health markets. As subscribers to the BioMedReports FDA Calendar know, one of these investigational products, Qnexa, is in Phase III clinical trials for obesity and in Phase II clinical trials for diabetes. As such, the speculation is that VIVUS would make it a great takeover target.